Guidant Rethinks Everolimus-Eluting Stent Platform Strategy, Timeframes
This article was originally published in The Gray Sheet
Executive Summary
Guidant acknowledges that its initial drug-eluting stent may have to be a cobalt-chromium, durable-polymer stent if design changes to the bioabsorbable-polymer Champion require renewed preclinical or clinical testing
You may also be interested in...
Guidant To Push DES Program In 2005, Says Champion Fracture Issue Solved
Guidant expects to launch its Champion everolimus drug-eluting stent in Europe in mid-2005, assuming regulators agree that the firm has resolved stress fracture problems related to the device
Guidant To Push DES Program In 2005, Says Champion Fracture Issue Solved
Guidant expects to launch its Champion everolimus drug-eluting stent in Europe in mid-2005, assuming regulators agree that the firm has resolved stress fracture problems related to the device
Guidant, Boston Scientific Stocks Weather DES Issues
Guidant's July 1 confirmation that design changes to its Champion everolimus drug-eluting stent will only delay a launch by six to eight months appears to have partially allayed investor concerns after an initial stock sell-off in May